Authors

• Vivian Yan Shi (ORCID: https://orcid.org/0000-0002-7510-9428)
• Robert Rolleri
• Linnea Thorlacius (ORCID: https://orcid.org/0000-0002-3734-9607)
• John R Ingram (ORCID: https://orcid.org/0000-0002-5257-1142)
• Sylke Schneider‐Burrus (ORCID: https://orcid.org/0000-0002-9740-6845)
• T. Vaux
• Martina Lee Porter (ORCID: https://orcid.org/0000-0002-4738-4385)
• Jérémy Lambert (ORCID: https://orcid.org/0000-0002-7164-1492)
• Koremasa Hayama (ORCID: https://orcid.org/0000-0001-8651-2493)
• Jacek Cezary Szepietowski (ORCID: https://orcid.org/0000-0003-0766-6342)
• Seth Forman (ORCID: https://orcid.org/0000-0001-5800-1856)
• Hadar Lev‐Tov (ORCID: https://orcid.org/0000-0001-6223-7001)
• Bartosz Lukowski (ORCID: https://orcid.org/0009-0008-0217-6313)

Institutions

• Nihon University (JP)
• Wrocław University of Science and Technology (PL)
• Beth Israel Deaconess Medical Center (US)
• Harvard University (US)
• University of Miami (US)
• University of Washington (US)
• Frederiksberg Hospital (DK)
• Wroclaw Medical University (PL)
• Zealand University Hospital (DK)
• UCB Pharma (France) (FR)
• AGH University of Krakow (PL)
• Cardiff University (GB)

Publication Details

Journal

Dermatology and Therapy

Published

2025-07-13

DOI

https://doi.org/10.1007/s13555-025-01465-4

Citations

1

Primary Topic

Hidradenitis Suppurativa and Treatments

Type

article

Field-Weighted Citation Impact

2.00

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Sanofi
• Biogen
• Regeneron Pharmaceuticals
• UCB
• Les Laboratories Pierre Fabre
• Incyte
• Horizon Therapeutics
• Eisai
• Galderma
• LEO Pharma
• Sanofi Genzyme